Journal of Vaccine Research 2024, Vol.14, No.4, 170-182 http://medscipublisher.com/index.php/jvr 181 Hadinegoro S., Arredondo-García J., Capeding M., Deseda C., Chotpitayasunondh T., Dietze R., Ismail H., Reynales H., Limkittikul K., Rivera-Medina D., Tran H., Bouckenooghe A., Chansinghakul D., Cortés M., Fanouillere K., Forrat R., Frago C., Gailhardou S., Jackson N., Noriega F., Plennevaux E., Wartel T., Zambrano B., and Saville M., 2015, Efficacy and long-term safety of a dengue vaccine in regions of endemic disease, New England Journal of Medicine, 373(13): 1195-1206. https://doi.org/10.1056/NEJMoa1506223 PMid:26214039 Halstead S.B., 2022, Is dengue vaccine protection possible?, Clinical Infectious Diseases, 74(1): 156-160. https://doi.org/10.1093/cid/ciab282 PMid:33788926 Huang C. H., Tsai Y. T., Wang S. F., Wang W. H., and Chen Y. H., 2021, Dengue vaccine: an update, Expert Review of Anti-Infective Therapy, 19(12): 1495-1502. https://doi.org/10.1080/14787210.2021.1949983 PMid:34182875 Kallas E. G., Precioso A. R., Palacios R., Thomé B., Braga P. E., Vanni T., Campos L.M.A., Ferrari L., Mondini G., da Graça Salomão M., da Silva A., Espinola H.M., do Prado Santos J., Santos C.L.S., Timenetsky M.C.S.T., Miraglia J.L., Gallina N.M.F., Weiskopf D., Sette A., Goulart R., Salles R.T., Maestri A., Sallum A.M.E., Farhat S.C.L., Sakita N.K., Ferreira J.C.O.A., Silveira C.G.T., Costa P.R., Raw I., Whitehead S.S., Durbin A.P., and Kalil J., 2020, Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial, The Lancet Infectious Diseases, 20(7): 839-850. https://doi.org/10.1016/S1473-3099(20)30023-2 PMid:32220283 Lanata C., Andrade T., Gil A., Terrones C., Valladolid O., Zambrano B., Saville M., and Crevat D., 2012, Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru, Vaccine, 30(41): 5935-5941. https://doi.org/10.1016/j.vaccine.2012.07.043 PMid:22863660 Lin L., Koren M.A., Paolino K.M., Eckels K.H., De La Barrera R., Friberg H., Currier J.R., Gromowski G.D., Aronson N.E., Keiser P.B., Sklar M.J., Sondergaard E.L., Jasper L.E., Endy T.P., Jarman R.G., and Thomas S.J., 2021, Immunogenicity of a live-attenuated dengue vaccine using a heterologous prime-boost strategy in a phase 1 randomized clinical trial, The Journal of Infectious Diseases, 223(10): 1707-1716. https://doi.org/10.1093/infdis/jiaa603 PMid:32966573 Pinheiro-Michelsen J.R., Souza R.D.S.O., Santana I.V.R., Da Silva P.D.S., Mendez E.C., Luiz W.B., and Amorim J.H., 2020, Anti-dengue vaccines: from development to clinical trials, Frontiers in Immunology, 11, 1252. https://doi.org/10.3389/fimmu.2020.01252 PMid:32655561 PMCid:PMC7325986 Prompetchara E., Ketloy C., Thomas S., and Ruxrungtham K., 2020, Dengue vaccine: Global development update, Asian Pac J Allergy Immunol, 38(3): 178-185. Rivera L., Biswal S., Sáez-Llorens X., Reynales H., López-Medina E., Borja-Tabora C., Bravo L., Sirivichayakul C., Kosalaraksa P., Vargas L., Yu D., Watanaveeradej V., Espinoza F., Dietze R., Fernando L., Wickramasinghe P., Moreira E., Fernando A., Gunasekera D., Luz K., Cunha R., Rauscher M., Zent O., Liu M., Hoffman E., Lefevre I., Tricou V., Wallace D., Alera M., and Borkowski A., 2022, Three-year efficacy and safety of Takeda's dengue vaccine candidate (TAK-003), Clinical Infectious Diseases, 75(1): 107-117. https://doi.org/10.1093/cid/ciab864 PMid:34606595 PMCid:PMC9402653 Rivera L., Biswal S., Sáez-Llorens X., Reynales H., López-Medina E., Borja-Tabora C., Bravo L., Sirivichayakul C., Kosalaraksa P., Vargas L.M., Yu D., Watanaveeradej V., Espinoza F., Dietze R., Fernando L., Wickramasinghe P., MoreiraJr E.D., Fernando A.D., Gunasekera D., Luz K., Cunha R.V., Rauscher M., Zent O., Liu M., Hoffman E., LeFevre I., Tricou V., Wallace D., Alera M.T., and Borkowski A., 2022, Three-year efficacy and safety of Takeda's dengue vaccine candidate (TAK-003), Clinical Infectious Diseases, 75(1): 107-117. https://doi.org/10.1093/cid/ciab864 PMid:34606595 PMCid:PMC9402653 Santos J., Montellano M. E., Solante R., Perreras N., Meyer S., Toh M. L., Zocchetti C., Vigne C., and Mascareñas C., 2021, Immunogenicity and safety of a tetravalent dengue vaccine administered concomitantly or sequentially with tdap vaccine: randomized phase IIIb trial in healthy participants 9-60 years of age in the Philippines, The Pediatric Infectious Disease Journal, 40(9): 856-863. https://doi.org/10.1097/INF.0000000000003220 PMid:34117198 PMCid:PMC8357045 Thomas S.J., 2023, Is new dengue vaccine efficacy data a relief or cause for concern?, NPJ Vaccines, 8(1): 55. https://doi.org/10.1038/s41541-023-00658-2 PMid:37061527 PMCid:PMC10105158 Tricou V., Sáez-Llorens X., Yu D., Rivera L., Jimeno J., Villarreal A. C., Dato E., de Suman O.S., Montenegro N., DeAntonio R., Mazara S., Vargas M., Mendoza D., Rauscher M., Brose M., Lefevre I., Tuboi S., Borkowski A. , and Wallace D., 2020, Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial, The Lancet, 395(10234): 1434-1443. https://doi.org/10.1016/S0140-6736(20)30556-0 PMid:32197107
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==